Infection with SARS-CoV-2 has adverse outcomes for individuals with particular comorbid diseases, e.g., hypertension, obesity, type 2 DM, and other CVDs and this may be due to the presence of pre-existing ED and systemic inflammation in subjects with these conditions ( Cardiovascular/cardiometabolic comorbidities such as coronary artery disease (ischemic heart disease, coronary heart disease), hypertension, and DM dramatically increase the risk of in-hospital mortality in COVID-19 patients ( Thus SARS-CoV-2 infection may cause persistent CV symptoms following recovery from acute COVID-19 ( In a US study including more than 150 000 individuals, 1 year after SARS-CoV-2 infection, a significantly increased risk of a variety of CVDs, including heart failure, dysrhythmias, myocardial infarction, and stroke, independent of the severity of initial COVID-19 presentation was observed ( SARS-CoV-2 infection can cause significant vascular pathology, cardiac injury, and acute and chronic CV complications
Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells
Substance P stimulates endothelin 1 secretion via endothelin-converting enzyme 1 and promotes melanogenesis in human melanocytes
The Emma testing measures mycotoxins and spores, whereas the Ermias just pause
